Read by QxMD icon Read

Current Oncology

S F Hall, R Griffiths
[This corrects the article on p. 266 in vol. 23, PMID: 27536177.].
October 2016: Current Oncology
H S Wald
No abstract text is available yet for this article.
October 2016: Current Oncology
P Vashi, E Abboud, C Bier-Laning, D Gupta
We present here a very rare clinical case of a 38-year-old man with Kaposiform hemangioendothelioma (khe) of the tongue who presented to our institution with a growth under the left side of the tongue with no pain or discomfort. There were no enlarged lymph nodes and no significant neurologic findings. Diagnostic histopathology confirmed the lesion to be khe. The tumour was removed surgically, and the surgical specimen confirmed the diagnosis. Follow-up at 3 months shows no clinical evidence of recurrence.
October 2016: Current Oncology
E J Chow, K D Bishop
CASE DESCRIPTION: A 60-year-old man developed painless neutropenic enterocolitis after induction chemotherapy for newly diagnosed acute myelogenous leukemia. The patient had recurrent fever while neutropenic, without experiencing abdominal pain or tenderness on physical examination. His diagnosis was delayed by the fact that he had no localizing symptoms. DISCUSSION: Neutropenic enterocolitis is a common complication, generally occurring in patients who are severely neutropenic; the condition presents with fever and abdominal pain...
October 2016: Current Oncology
J Sussman, N P Varela, M Cheung, L Hicks, D Kraftcheck, J Mandel, G Fraser, L Jimenez-Juan, A Boudreau, S Sajkowski, R McQuillan
OBJECTIVE: This evidence summary set out to assess the available evidence about the follow-up of asymptomatic survivors of lymphoma who have received curative-intent treatment. METHODS: The medline and embase databases and the Cochrane Database of Systematic Reviews were searched for evidence published between 2000 and August 2015 relating to lymphoma survivorship follow-up. The evidence summary was developed by a Working Group at the request of the Cancer Care Ontario Survivorship and Cancer Imaging programs because of the absence of evidence-based practice documents in Ontario for the follow-up and surveillance of asymptomatic patients with lymphoma in complete remission...
October 2016: Current Oncology
V D'Souza, H Daudt, A Kazanjian
AIM: In the present study, we synthesized the published literature about the psychosocial aspects of colorectal cancer (crc) survivorship to support an update of the evidentiary base of the survivorship care plans (scps) created in our jurisdiction. METHODS: The psychosocial topics identified in the crc scps created by two different initiatives in our province were used as search criteria: quality of life (qol), sexual function, fatigue, and lifestyle behaviors...
October 2016: Current Oncology
M S Władysiuk, R Mlak, K Morshed, W Surtel, A Brzozowska, T Małecka-Massalska
BACKGROUND: Phase angle could be an alternative to subjective global assessment for the assessment of nutrition status in patients with head-and-neck cancer. METHODS: We prospectively evaluated a cohort of 75 stage iiib and iv head-and-neck patients treated at the Otolaryngology Department, Head and Neck Surgery, Medical University of Lublin, Poland. Bioelectrical impedance analysis was performed in all patients using an analyzer that operated at 50 kHz. The phase angle was calculated as reactance divided by resistance (Xc/R) and expressed in degrees...
October 2016: Current Oncology
A Salman, E Simoneau, M Hassanain, P Chaudhury, L M Boucher, D Valenti, T Cabrera, C Nudo, P Metrakos
BACKGROUND AND AIMS: In this pilot study, we assessed the safety and tolerability of combining sorafenib with (90)Y radioembolization for the treatment of unresectable hepatocellular carcinoma (hcc). METHODS: The study, conducted prospectively during 2009-2012, included eligible patients with unresectable hcc and a life expectancy of at least 12 weeks. Each patient received sorafenib (400 mg twice daily) for 6-8 weeks before (90)Y treatment. Safety and tolerability were assessed...
October 2016: Current Oncology
A Mamo, A Baig, M Azam, Y S Rho, S Sahebjam, T Muanza, S Owen, K Petrecca, M C Guiot, J Al-Shami, R Sharma, P Kavan
BACKGROUND: The use of bevacizumab in the management of glioblastoma multiforme (gbm) remains controversial. In Canada, bevacizumab is approved for the treatment of recurrent gbm. We describe a pattern of progression across treatment lines in gbm. METHODS: During 2008-2014, 64 patients diagnosed with gbm were treated with bevacizumab at McGill University hospitals. Of those patients, 30 (46.9%) received bevacizumab in the first line (B1L), and 34 (53.1%) received it in the second line and beyond (B2L+)...
October 2016: Current Oncology
M Duong, E Wright, L Yin, I Martin-Nunez, P Ghatage, M Fung-Kee-Fung
BACKGROUND: The overall survival (os) analysis of the icon7 trial demonstrated that frontline ovarian cancer patients with a high risk of progression (stage iii suboptimally debulked, and stage iii or iv with unresectable disease) benefited from the addition of bevacizumab to standard chemotherapy compared with standard chemotherapy alone. The objective of the present study was to investigate the cost-effectiveness, from a Canadian publicly funded perspective, of adding bevacizumab to frontline treatment of ovarian cancer at high risk of progression...
October 2016: Current Oncology
N Samuel, S Verma
BACKGROUND: The primary objective of the present study was to examine the drug approval process and the time to approval (tta) for cancer drugs by 3 major international regulatory bodies-Health Canada, the U.S. Food and Drug Administration (fda), and the European Medicines Agency (ema)-and to explore differences in the drug approval processes that might contribute to any disparities. METHODS: The publicly available Health Canada Drug Product Database was surveyed for all marketed antineoplastic agents approved between 1 January 2005 and 1 June 2013...
October 2016: Current Oncology
M D Krahn, K E Bremner, J Luo, G Tomlinson, S M H Alibhai
BACKGROUND: Comparing relative costs for androgen deprivation therapy (adt) protocols in prostate cancer (pca) requires an examination of all health care resources, not only those specific to pca. The objective of the present study was to use administrative data to estimate total health care costs in a population-based cohort of pca patients. METHODS: Patients in Ontario with pca who started 90 days or more of adt at age 66 years or older during 1995-2005 were selected from cancer registry and health care administrative databases...
October 2016: Current Oncology
Y Hashiguchi, M Kasai, T Fukuda, T Ichimura, T Yasui, T Sumi
BACKGROUND: No potential tumour markers have been validated for prognosis in endometrial cancer. However, carcinoembryonic antigen (cea) is one of the most widely used tumour markers in various types of cancer. Although cea expression in endometrial cancer has been investigated, its prognostic value remains controversial, and no studies have investigated serum cea levels in large case series. In the present study, we investigated diagnostic and prognostic applications of serum cea for endometrial cancer...
October 2016: Current Oncology
N Mills
No abstract text is available yet for this article.
October 2016: Current Oncology
K C Y Yiu, J N Greenspoon
INTRODUCTION: After stereotactic radiosurgery (srs) for brain metastases, patients are routinely monitored with magnetic resonance imaging (mri). The high rate of new brain metastases after srs treatment alone might not be as concerning with modern mri and target localization treatment. Intensive surveillance might induce anxiety, lowering the patient's quality of life (qol). The present work is the feasibility component of a prospective study evaluating the role of surveillance mri on qol in patients with limited (1-3) brain metastases...
October 2016: Current Oncology
K Tran, R Rahal, M Brundage, S Fung, C Louzado, M Milosevic, J Xu, H Bryant
BACKGROUND: As part of Choosing Wisely Canada (a national campaign to encourage patient-provider conversations about unnecessary medical tests, treatments, and procedures), a list of ten oncology practices that could be low-value in some instances was developed. Of those practices, two were specific to radiation therapy (rt): conventional fractionation as part of breast-conserving therapy (bct) for women with early-stage breast cancer, and multifraction radiation for palliation of uncomplicated painful bone metastases...
October 2016: Current Oncology
T Le, E B Kennedy, J Dodge, L Elit
BACKGROUND: A need for follow-up recommendations for survivors of fallopian tube, primary peritoneal, or epithelial ovarian cancer after completion of primary treatment was identified by Cancer Care Ontario's Program in Evidence-Based Care. METHODS: We searched for existing guidelines, conducted a systematic review (medline, embase, and cdsr, January 2010 to March 2015), created draft recommendations, and completed a comprehensive review process. Outcomes included overall survival, quality of life, and patient preferences...
October 2016: Current Oncology
D J Kagedan, M E Dixon, R S Raju, Q Li, M Elmi, E Shin, N Liu, A El-Sedfy, L Paszat, A Kiss, C C Earle, N Mittmann, N G Coburn
BACKGROUND: In the present study, we aimed to describe, at the population level, patterns of adjuvant treatment use after curative-intent resection for pancreatic adenocarcinoma (pcc) and to identify independent predictors of adjuvant treatment use. METHODS: In this observational cohort study, patients undergoing pcc resection in the province of Ontario (population 13 million) during 2005-2010 were identified using the provincial cancer registry and were linked to administrative databases that include all treatments received and outcomes experienced in the province...
October 2016: Current Oncology
M Y Ho, D J Renouf, W Y Cheung, H J Lim, C H Speers, C Zhou, H F Kennecke
BACKGROUND: Therapy with anti-epidermal growth factor receptor (egfr) monoclonal antibody improves outcomes for patients with metastatic colorectal cancer (mcrc) in the first-, second-, and third-line trial settings. In British Columbia, the use of egfr inhibitors (egfris) is confined to third-line therapy, which might lower the proportion of patients who receive this therapy. The objective of the present study was to describe egfri treatment patterns when those agents are limited to the third-line setting...
October 2016: Current Oncology
C Skedgel
The pan-Canadian Oncology Drug Review (pcodr) is responsible for making coverage recommendations to provincial and territorial drug plans about cancer drugs. Within the pcodr process, small groups of experts (including public representatives) consider the characteristics of each drug and make a funding recommendation. It is important to understand how the values and preferences of those decision-makers compare with the values and preferences of the citizens on whose behalf they are acting. In the present study, stated preference methods were used to elicit prioritization preferences from a representative sample of the Canadian public and a small convenience sample of pcodr committee members...
October 2016: Current Oncology
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"